vs

Side-by-side financial comparison of Royalty Pharma plc (RPRX) and Tri Pointe Homes, Inc. (TPH). Click either name above to swap in a different company.

Tri Pointe Homes, Inc. is the larger business by last-quarter revenue ($972.6M vs $622.0M, roughly 1.6× Royalty Pharma plc). Royalty Pharma plc runs the higher net margin — 34.4% vs 6.2%, a 28.3% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs -22.4%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 1.8%).

Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.

Tri Pointe Homes, Inc. is a home construction company headquartered in Incline Village, Nevada. It also offers financing and insurance services to homebuyers. It operates in Arizona, California, Nevada, Washington, Colorado, Texas, the District of Columbia, Maryland, North Carolina, South Carolina, and Virginia. The company is the 18th largest home construction company in the United States based on the number of homes closed.

RPRX vs TPH — Head-to-Head

Bigger by revenue
TPH
TPH
1.6× larger
TPH
$972.6M
$622.0M
RPRX
Growing faster (revenue YoY)
RPRX
RPRX
+27.2% gap
RPRX
4.8%
-22.4%
TPH
Higher net margin
RPRX
RPRX
28.3% more per $
RPRX
34.4%
6.2%
TPH
Faster 2-yr revenue CAGR
RPRX
RPRX
Annualised
RPRX
4.6%
1.8%
TPH

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
RPRX
RPRX
TPH
TPH
Revenue
$622.0M
$972.6M
Net Profit
$214.2M
$60.2M
Gross Margin
Operating Margin
62.4%
8.1%
Net Margin
34.4%
6.2%
Revenue YoY
4.8%
-22.4%
Net Profit YoY
2.9%
-53.4%
EPS (diluted)
$0.49
$0.70

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RPRX
RPRX
TPH
TPH
Q4 25
$622.0M
$972.6M
Q3 25
$609.3M
$854.7M
Q2 25
$578.7M
$902.4M
Q1 25
$568.2M
$740.9M
Q4 24
$593.6M
$1.3B
Q3 24
$564.7M
$1.1B
Q2 24
$537.3M
$1.2B
Q1 24
$568.0M
$939.4M
Net Profit
RPRX
RPRX
TPH
TPH
Q4 25
$214.2M
$60.2M
Q3 25
$288.2M
$56.1M
Q2 25
$30.2M
$60.7M
Q1 25
$238.3M
$64.0M
Q4 24
$208.2M
$129.2M
Q3 24
$544.0M
$111.8M
Q2 24
$102.0M
$118.0M
Q1 24
$4.8M
$99.1M
Operating Margin
RPRX
RPRX
TPH
TPH
Q4 25
62.4%
8.1%
Q3 25
70.1%
8.1%
Q2 25
36.3%
8.5%
Q1 25
94.0%
10.4%
Q4 24
60.9%
13.4%
Q3 24
12.6%
Q2 24
50.2%
12.9%
Q1 24
-13.0%
12.3%
Net Margin
RPRX
RPRX
TPH
TPH
Q4 25
34.4%
6.2%
Q3 25
47.3%
6.6%
Q2 25
5.2%
6.7%
Q1 25
41.9%
8.6%
Q4 24
35.1%
10.3%
Q3 24
96.3%
9.8%
Q2 24
19.0%
10.2%
Q1 24
0.8%
10.5%
EPS (diluted)
RPRX
RPRX
TPH
TPH
Q4 25
$0.49
$0.70
Q3 25
$0.67
$0.64
Q2 25
$0.07
$0.68
Q1 25
$0.55
$0.70
Q4 24
$0.46
$1.37
Q3 24
$1.21
$1.18
Q2 24
$0.23
$1.25
Q1 24
$0.01
$1.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RPRX
RPRX
TPH
TPH
Cash + ST InvestmentsLiquidity on hand
$618.7M
$982.8M
Total DebtLower is stronger
$9.0B
Stockholders' EquityBook value
$9.7B
$3.3B
Total Assets
$19.6B
$5.0B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RPRX
RPRX
TPH
TPH
Q4 25
$618.7M
$982.8M
Q3 25
$938.9M
$792.0M
Q2 25
$631.9M
$622.6M
Q1 25
$1.1B
$812.9M
Q4 24
$929.0M
$970.0M
Q3 24
$950.1M
$676.0M
Q2 24
$1.8B
$492.9M
Q1 24
$843.0M
$944.0M
Total Debt
RPRX
RPRX
TPH
TPH
Q4 25
$9.0B
Q3 25
$8.9B
Q2 25
$8.0B
Q1 25
$7.6B
Q4 24
$7.6B
$646.5M
Q3 24
$7.6B
Q2 24
$7.6B
Q1 24
$6.1B
Stockholders' Equity
RPRX
RPRX
TPH
TPH
Q4 25
$9.7B
$3.3B
Q3 25
$9.6B
$3.3B
Q2 25
$9.5B
$3.3B
Q1 25
$9.8B
$3.3B
Q4 24
$10.3B
$3.3B
Q3 24
$10.3B
$3.2B
Q2 24
$9.8B
$3.1B
Q1 24
$9.9B
$3.0B
Total Assets
RPRX
RPRX
TPH
TPH
Q4 25
$19.6B
$5.0B
Q3 25
$19.3B
$5.0B
Q2 25
$18.3B
$4.8B
Q1 25
$17.6B
$4.8B
Q4 24
$18.2B
$4.9B
Q3 24
$18.0B
$4.8B
Q2 24
$17.7B
$4.6B
Q1 24
$16.1B
$5.0B
Debt / Equity
RPRX
RPRX
TPH
TPH
Q4 25
0.92×
Q3 25
0.93×
Q2 25
0.84×
Q1 25
0.78×
Q4 24
0.74×
0.19×
Q3 24
0.74×
Q2 24
0.78×
Q1 24
0.62×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RPRX
RPRX
TPH
TPH
Operating Cash FlowLast quarter
$827.1M
$221.0M
Free Cash FlowOCF − Capex
$213.2M
FCF MarginFCF / Revenue
21.9%
Capex IntensityCapex / Revenue
0.8%
Cash ConversionOCF / Net Profit
3.86×
3.67×
TTM Free Cash FlowTrailing 4 quarters
$128.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RPRX
RPRX
TPH
TPH
Q4 25
$827.1M
$221.0M
Q3 25
$702.6M
$45.9M
Q2 25
$364.0M
$-74.3M
Q1 25
$596.1M
$-31.2M
Q4 24
$742.5M
$360.3M
Q3 24
$703.6M
$167.9M
Q2 24
$658.2M
$23.1M
Q1 24
$664.6M
$144.7M
Free Cash Flow
RPRX
RPRX
TPH
TPH
Q4 25
$213.2M
Q3 25
$39.1M
Q2 25
$-84.5M
Q1 25
$-39.3M
Q4 24
$355.9M
Q3 24
$161.5M
Q2 24
$17.0M
Q1 24
$138.3M
FCF Margin
RPRX
RPRX
TPH
TPH
Q4 25
21.9%
Q3 25
4.6%
Q2 25
-9.4%
Q1 25
-5.3%
Q4 24
28.4%
Q3 24
14.1%
Q2 24
1.5%
Q1 24
14.7%
Capex Intensity
RPRX
RPRX
TPH
TPH
Q4 25
0.8%
Q3 25
0.8%
Q2 25
1.1%
Q1 25
1.1%
Q4 24
0.3%
Q3 24
0.6%
Q2 24
0.5%
Q1 24
0.7%
Cash Conversion
RPRX
RPRX
TPH
TPH
Q4 25
3.86×
3.67×
Q3 25
2.44×
0.82×
Q2 25
12.06×
-1.22×
Q1 25
2.50×
-0.49×
Q4 24
3.57×
2.79×
Q3 24
1.29×
1.50×
Q2 24
6.45×
0.20×
Q1 24
139.10×
1.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

RPRX
RPRX

Financial Royalty Assets$592.4M95%
Royalty Income Other$29.6M5%

TPH
TPH

West$547.8M56%
Central$245.1M25%
East$161.8M17%
Financial Services Segment$18.0M2%
Land$7.9M1%

Related Comparisons